#microarray studies

[crimsonpublishers-oabb]

Artificial Cell Membranes as Bioinformation Hubs: Unraveling Therapeutic Networks through Nano-Informatics

The living cells are composed of bio-membranes which construct lipid bilayers composed mainly of phospholipids with proteins and cholesterol embedded in them. The internal organelles of the cell are composed of intracellular membranes and their unique structure modulates the permeation of molecules, like water, ions, and oxygen. Bio-membranes are considered as complex systems, and their state of matter is the liquid crystalline state corresponds to the fluid mosaic model of Singer & Nicolson [1]. Such state of matter undergoes a huge number of metastable phases that are named as ‘lipid rafts’ that are considered to act as information hubs.

These ‘lipid rafts’ are thermodynamic driven bioinformation hubs essential for the cell functions and for the survival of the organism [2]. The convergence of various scientific disciplines, including bioinformatics, cheminformatics, medical informatics, and nanoinformatics, has given rise to novel approaches in understanding and harnessing the potential of artificial cell membranes as bioinformation hubs. This paper delves into the intricate interplay between bio-membranes, lipid rafts, and thermodynamic-driven bioinformation, elucidating their pivotal role in establishing therapeutic networks.

Read More About This Article: https://crimsonpublishers.com/oabb/fulltext/OABB.000566.php

Read More About Crimson Publishers: https://crimsonpublishers.com/oabb/index.php

[industryupdate]

North America Led the Carrier Screening Industry

The carrier screening market is experiencing significant growth, and it will continue like this throughout this decade.

The progression of this industry is because of the rising occurrence of genetic ailments, increasing count of enhanced product launches, and growing affordability and accessibility of tests.

In the past few years, the expanded carrier screening category, based on type, was the largest contributor to the industry. This is because of the extensive utilization of next-generation sequencing and numerous other advanced technologies for carrier screening all over the world. Furthermore, the extended method of carrier screening enables the testing for numerous illnesses at once.

On the basis of application, the cystic fibrosis category led the industry, and it will further advance at the fastest rate in the years to come. This can be primarily attributed to the mounting incidence of cystic fibrosis in Europe and North America.

Furthermore, the increasing public consciousness regarding this illness, coupled with the importance of its early diagnosis is boosting the need for genetic testing for this health disorder.

Based on technology, the DNA sequencing category led the carrier screening market, and it will further propel at the highest rate during this decade. This can be because of its cost-effectiveness, along with the fact that it does not necessitate expertise in the bioinformatics domain.

On the basis of end user, the hospitals category is likely to grow at the highest CAGR, during this decade. This can be primarily because of the surge in the usage of genetic illness testing kits by healthcare providers in this healthcare setting.

Furthermore, numerous insurance and policies companies are offering reimbursements for such tests, this will also assist the expansion of this category.

North America dominated the industry in recent years, and it will continue this trend throughout this decade. This is because of the increase in the number of tests being performed to identify whether a person is a carrier or at risk of any genetic ailment.

APAC will grow at the highest rate in the years to come. This is due to the increasing consciousness of such genetic screening tests in Australia, India, and China; and growing worries of people regarding the well-being of their future children.

In addition, in APAC, China and India are the two most extremely populated countries, with a high incidence of genetic illnesses. This is also boosting the requirement for screening procedures, assisting in the further progression of the regional industry.

With the surging prevalence of genetic ailments, coupled with the rising affordability and accessibility of tests, the carrier screening industry will continue to grow significantly in the years to come.

[shalomniscient]

Oh! If you're talking about not quite fox Feixiao can I offer the Caninae subfamily Lycalopex?. They're the south American foxes. However taxonomically they're more closely related to wolves than to foxes despite their appearance. And are an example of convergent evolution.

I was thinking of giving one to Feixiao in a Daemon AU (From his dark materials). It was a way to combine my private writting with my current studies in a biology stem field. (You see a lot about taxonomy in bioinformatics)

anon i need you to know that you sent me down a rabbithole about lycalopex. i was reading papers and articles last night about phylogeny and taxa like it was BAD (read: good. very incredibly good and fun). i studied some bioinformatics in school a few years back (really basic microarrays and gene sequencing) and i found it really intersting, even if complicated. taxonomy on the other hand is a huge part of my current envirosci course and i LOVEEEE it !! phylogenetic trees are my favourite kind of diagram <333 in any case, is see where you’re coming from from the not-quite-fox angle but i personally my borzoi interpretation more, both because dogs are direct descendants of wolves and the borzoi specifically as a breed as bred to hunt wolves. it’s the themes, you understand.

also, HDM !!! wow i haven’t thought of this franchise in years… admittedly i neither watched the netflix show nor read any other book besides la belle sauvage from the prequel (?) series the book of dust having picked it up as an in-flight read while i was travelling with my family. i wasn’t as invested in the characters (go figure, since i didn’t read any of the other works lmao) but i was super drawn in by the concept of hdm’s dæmons. i’ve always maintained that if i had one it’d be a fox LMAO but i can see the vision of fei having a dæemon from genus lycalopex !! i still maintain that a borzoi would also be pretty cool though 👉👈

[everythingaboutbiotech]

Common uses of bioinformatics

💡Sequence analysis Analyzing DNA and protein sequences to identify genes, regulatory regions & mutations.

💡Gene expression Analyzing RNA expression data from experiments like microarrays or RNA-seq to understand gene regulation.

💡Phylogenetics Constructing evolutionary relationships between organisms based on genetic data and genomic comparisons.

💡Molecular modeling Predicting protein structure and docking drugs to proteins using computational modeling and simulation.

💡Databases & Data mining Developing databases like GenBank to store biological data and mining it to find patterns.

💡Genomics Studying entire genomes, including sequencing and assembling genomes as well as identifying genes and genomic variations.

Follow @everythingaboutbiotech for useful posts.

[screenshots123]

The study, published Jan. 24 in Nature, shows that approximately 20% to 25% of patients with multiple sclerosis have antibodies in their blood that bind tightly to both a protein from the Epstein-Barr virus, called EBNA1, and a protein made in the brain and spinal cord, called the glial cell adhesion molecule, or GlialCAM.

“Part of the EBV protein mimics your own host protein — in this case, GlialCAM, found in the insulating sheath on nerves,” said William Robinson, MD, PhD, professor of immunology and rheumatology at Stanford. “This means that when the immune system attacks EBV to clear the virus, it also ends up targeting GlialCAM in the myelin.”

Myelin forms the protective coating around nerve cells, and when it’s damaged, electrical impulses can no longer jump efficiently from one nerve to the next, resulting in the numbness, muscle weakness and severe fatigue of multiple sclerosis. Previous research has shown that multiple sclerosis patients have increased antibodies to a variety of common viruses, including measles, mumps, varicella-zoster and Epstein-Barr virus. In fact, more than 99% of MS patients have EBV antibodies in their blood, indicating a prior infection, compared with 94% of healthy individuals. But despite this epidemiologic correlation, scientists have struggled to prove a causal connection.

“Nobody really knows what causes autoimmune diseases, and for many decades, all sorts of different viruses have been hypothesized,” Robinson said. “But when people did further mechanistic digging, everything fell apart, and it turned out that getting those other viruses didn’t actually cause MS.”

To search for this elusive mechanistic link, the researchers started by examining the antibodies produced by immune cells in the blood and spinal fluid of nine MS patients. Unlike in healthy individuals, the immune cells of MS patients traffic to the brain and spinal cord, where they produce large amounts of a few types of antibodies. Patterns of these antibody proteins, called oligoclonal bands, are found during analysis of the spinal fluid and are part of the diagnostic criteria for MS.

“No one knows exactly what those antibodies bind to or where they’re from,” Robinson said. “So the first thing we did was analyze the antibodies from the oligoclonal bands, and showed that they come from B cells in the spinal fluid.”

Lanz said. “What we did was a different approach: We took B cells from the spinal fluid, single-cell sorted them and sequenced each one separately. In a single-cell format and at the scale of tens to hundreds of B cells per patient, that had not been done before.”

Once the researchers determined that the oligoclonal bands in MS are produced by the sorted B cells in the spinal fluid, they expressed individual antibodies from these cells and tested them for reactivity against hundreds of different antigens.

“We started with human antigens,” Robinson said, “but couldn’t find clear reactivity. So eventually we tested them against EBV and other herpes viruses, and lo and behold, several of these antibodies, and one in particular, bound to EBV.”

Six of the nine MS patients had antibodies that bound to the EBV protein EBNA1, and eight of nine had antibodies to some fragment of EBNA1. The researchers focused on one antibody that binds EBNA1 in a region known to elicit high reactivity in MS patients. They were then able to solve the crystal structure of the antibody-antigen complex, to determine which parts were most important for binding.

Before this discovery, Robinson said he’d been unconvinced that EBV caused MS. “We all thought it was just kind of an artifact; we didn’t really think it was causative. But when we found these antibodies that bound EBV in the spinal fluid, produced by the spinal fluid B cells, it made us revisit the potential association that we’d dismissed.” Next, the researchers tested the same antibody on a microarray containing more than 16,000 human proteins. When they discovered that the antibody also bound with high affinity to GlialCAM, they knew they’d found a specific mechanism for how EBV infection could trigger multiple sclerosis.

“EBV tricks the immune system into responding not only to the virus, but also to this critical component of the cells that make up the white matter in our brains,” Steinman said. “To use a military metaphor, it’s like friendly fire: In fighting the virus, we damage our own army.” 

To find out what percentage of MS might be caused by this so-called “molecular mimicry” between EBNA1 and GlialCAM, the researchers looked at a broader sample of MS patients and found elevated reactivity to the EBNA1 protein and GlialCAM in 20% to 25% of blood samples in three separate MS cohorts.

“Twenty-five percent is a conservative number,” Robinson said, noting that it doesn’t include patients who may have previously reacted to GlialCAM following EBV infection but whose immune response has evolved since the initial trigger. 

In fact, a study of 801 MS cases from more than 10 million active-duty military personnel over 20 years found that EBV infection was present in all but one case at the time of MS onset. A paper describing that study, published this month in Science, found that of 35 people who were initially EBV-negative, all but one became infected with EBV before the onset of MS. In addition, this separate group of researchers identified the same EBNA1 region as a major antibody target in MS patients. Together with the discovery of EBNA1/GlialCAM cross-reactivity, this data provides compelling evidence that EBV is the trigger for the vast majority of MS cases, as Robinson and Steinman point out in a Science Perspective, also published in January.

📅 Jan 2022 📰 Study identifies how Epstein-Barr virus triggers multiple sclerosis

[tech-romancy]

I'm going to add some context here. One of the reasons that "analytical ai" is less resource intensive is because generative ai models, to be useful, have to be retrained by data annotaters (sp?) constantly. Also a friend reminded me of the tb ai study that just learned that older machines were more likely to show positive tb results because of the socioeconomic forces that people with less resources tend to get tb more. https://www.nature.com/articles/s41467-024-50285-1 Here is the link to the original article With the understanding that I know nothing about biology, it seems the researchers built their own dataset using just one machine: [quote] we generated a large-scale tissue microarray imaging dataset, stained for chromatin using Hoechst, from 560 tissue samples from 122 patients at 3 disease stages and 11 phenotypic categories.

so it seems they got all confirmed cases, but three different stages of the specific tumor type, and made their own tissue images with the same microarray

[quote] The single chromatin stain, which is much cheaper and easier to obtain than sequencing or multiplexed imaging, enabled us to carry out a large-scale study of different disease stages and phenotypic categories, including normal breast tissue, hyperplasia, DCIS, and IDC (Fig. 1a) and the real innovation is the fact that they can use the cheaper stain vs more complex imagery. But it isn't an instance where they are pulling from open source data, but an instance of making their own dataset

[navyasri1]

RNA Analysis/Transcriptomics Market - Forecast(2024 - 2030)

Transcriptomics/RNA analysis can be defined as the study of the transcriptome or the complete set of RNA transcripts which are produced by the genome, under specific circumstances, environment or in a specific cell - using high-throughput methods, such as microarray analysis. Globally increasing R&D activities in RNA sequencing and trascriptomics is expected to remain key growth driver for the RNA analysis market during the period of study.

[industrynewsupdates]

Bioinformatics Market Insights: Opportunities and Challenges

The global bioinformatics market was valued at USD 10.1 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 13.7% from 2023 to 2030. Several key factors are driving this growth, including the increasing demand for bioinformatics tools and software in novel drug research and development (R&D), as well as both private and public funding initiatives that are aimed at supporting R&D activities. Additionally, the introduction of user-friendly bioinformatics software such as RasMol, AUTODOCK, BALL, and Bioclipse has played a significant role in expanding the market. These software tools are widely used for the accurate analysis of biomarker discovery programs, which help in detecting toxicity during the early stages of the drug development process.

Advancements in DNA sequencing are also contributing to the growth of the bioinformatics market. For example, a study published by Stanford Medicine in January 2022 demonstrated a DNA sequencing technique capable of sequencing a human genome in about 8 hours. Such breakthroughs enhance the demand for genomics, thereby driving the bioinformatics sector. Bioinformatics applications in data storage and analysis are crucial for managing large volumes of genomic and proteomic data, which facilitate research in various fields, including aging, carcinogenesis, and genetic disease prevention. This growing capacity to store and analyze vast amounts of data is expected to significantly contribute to market expansion over the forecast period.

Gather more insights about the market drivers, restrains and growth of the Bioinformatics Market

Product Insights

In terms of product categories, the bio-content management segment held the largest market share in 2022, accounting for 39.6% of the total market revenue. This can be attributed to the widespread use of bioinformatics tools in database management. These tools facilitate efficient data sharing with external databases and resources, thereby promoting data integration across various platforms. Genetic sequence analysis platforms are also poised to experience significant growth, driven by the increased demand for whole-genome sequencing and exome sequencing technologies, which have become more affordable due to reduced sequencing costs.

Bioinformatics is governed by various guidelines set by organizations such as the Human Genome Variation Society (HGVS), the Genomic Data Commons (GDC), and the Minimum Information About a Microarray Experiment (MIAME). Compliance with these standards ensures improved data compatibility, sharing, and collaboration. A noteworthy example of collaboration in this field occurred in April 2022, when ATCC entered into a partnership with Qiagen to share sequencing data from its collection of animal and human cell lines. This partnership aims to create a comprehensive database to aid in the development of therapeutic targets and the understanding of new diseases, which is crucial for both the pharmaceutical and biotechnology industries.

The bioinformatics market is divided into three primary product categories: bioinformatics platforms, bioinformatics services, and bio-content management. Among these, the bioinformatics services segment is expected to grow at the fastest rate, with a projected CAGR of 14.6% during the forecast period. Genomics has been the primary application area for bioinformatics, focusing on the analysis of entire DNA sequences. The increasing availability of genetic data, especially through next-generation sequencing (NGS) technologies, is driving demand for bioinformatics services, both in genomic research and clinical applications.

For instance, in July 2021, the National Institute of Technology in Rourkela, India, launched the Centre for Bioinformatics and Computational Biology (CBCB). This center focuses on the development of biomarkers and therapeutic strategies for various diseases using big data analytics, further boosting bioinformatics research and market growth, particularly in emerging markets.

The bioinformatics platforms segment is also expected to experience significant growth, driven by the increasing volume and complexity of biological data, the growing demand for personalized medicine, and the rise of cloud computing. The adoption of cloud-based platforms in bioinformatics enables better data sharing and collaboration between academic institutions, research organizations, and healthcare providers. Additionally, advancements in sequencing technologies continue to propel the demand for bioinformatics platforms.

Furthermore, the introduction of new and innovative technologies is expected to drive market expansion. For example, in June 2022, My Intelligent Machines (MIMs) launched software designed for drug development in oncology. Similarly, in March 2022, ARUP launched Rio, a bioinformatics analytics platform that streamlines results for next-generation sequencing tests. These developments highlight the increasing integration of bioinformatics into drug discovery and diagnostic workflows, further contributing to the market’s growth.

Order a free sample PDF of the Bioinformatics Market Intelligence Study, published by Grand View Research.

[insightfulblogz]

Glycomics Market Application Scope And Opportunities By 2032

Glycomics, the comprehensive study of glycans (sugar chains) and their biological roles, is an emerging field in biomedical research that provides insight into cellular processes, disease mechanisms, and therapeutic development. Glycans are essential molecules involved in cellular communication, immune response, and protein stability, among other functions. Through glycomics, researchers can analyze complex carbohydrate structures and their interactions, improving our understanding of diseases like cancer, autoimmune disorders, and infectious diseases. This field has broad applications in diagnostics, therapeutics, and personalized medicine.

The Glycomics Market size was estimated at USD 1.7 billion in 2022 and is expected to reach USD 5.09 billion by 2030 with a growing CAGR of 14.7% during the forecast period of 2023-2030.

Future Scope

The future of glycomics holds potential for significant breakthroughs in disease understanding and treatment. By integrating glycomics with genomics and proteomics, researchers can create a more comprehensive picture of disease mechanisms at the molecular level. Advancements in analytical techniques, such as mass spectrometry and glycan microarrays, will enable more precise glycan profiling, paving the way for new diagnostic biomarkers and therapeutic targets. Furthermore, as personalized medicine gains traction, glycomics will play a critical role in tailoring treatments based on individual glycan profiles, leading to more effective and targeted interventions in disease management.

Trends

Current trends in glycomics include the use of advanced analytical tools like high-throughput glycan analysis and computational modeling to decode glycan structures and functions. The field is also seeing a surge in glycoengineering, where synthetic glycans are designed for therapeutic use, enhancing drug delivery and efficacy. Another growing trend is the exploration of glycans in immunotherapy, where researchers investigate how glycans influence immune cell responses to cancer and infections. These advancements are expanding glycomics applications in healthcare, contributing to improved diagnostic and therapeutic options.

Applications

Glycomics has diverse applications in understanding diseases, developing biomarkers, and improving therapeutics. In cancer research, glycomics aids in identifying glycan-based biomarkers that can differentiate cancer cells from normal cells, supporting early detection and treatment. In infectious diseases, glycan profiling helps uncover pathogen-host interactions, informing vaccine development. Glycomics is also applied in drug development, as glycan engineering enhances drug stability and delivery. These applications make glycomics invaluable in advancing diagnostic precision, treatment effectiveness, and drug innovation.

Key Points

Glycomics studies glycans to understand cellular processes and disease mechanisms.

Future advancements will include glycomics integration with genomics for targeted therapies.

Trends include high-throughput glycan analysis, glycoengineering, and glycan-based immunotherapies.

Applications span cancer biomarker identification, infectious disease insights, and drug development.

Get a Free Sample Copy of the Report: https://www.snsinsider.com/sample-request/4084 

Conclusion

Glycomics is poised to make a lasting impact on modern medicine by uncovering the complex roles of glycans in health and disease. With the integration of new technologies and cross-disciplinary research, glycomics offers promising solutions for early diagnosis, personalized treatments, and innovative therapeutics. As this field progresses, glycomics will continue to be a cornerstone in the development of more accurate diagnostic tools and effective treatments, improving patient care and advancing biomedical research.

[farmacuticals]

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

[latestmarketresearchnews]

Biopreservation Market Growth Drivers With Outlook And Opportunity Forecast To 2030

The global biopreservation market was valued at USD 2.18 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 28.30% from 2023 to 2030. The rapid growth of this market is driven by a variety of factors, including the extensive use of biopreservation in hospitals, research labs, and healthcare facilities. Increased funding from both government entities and private organizations in healthcare is bolstering this growth, alongside a rise in research and development activities. In addition, advancements in product development are contributing to the expanding market. For instance, BioLife Solutions introduced a high-capacity controlled freezer in April 2021, targeting the cell and gene therapy market, which enabled the company to extend its product offerings.

Despite the market's expansion, the COVID-19 pandemic posed significant challenges, such as supply chain disruptions, shortages of raw materials, and interruptions to research activities. However, the pandemic also accelerated the development of novel biologics and vaccine technologies, creating a surge in demand for biologics manufacturing and preservation. As a result, opportunities for biopreservation are expected to increase, further boosting the market.

Gather more insights about the market drivers, restrains and growth of the Biopreservation Market

Biopreservation involves maintaining the integrity and functionality of biological materials such as stem cells, DNA, tissues, and organs by storing them at specific temperatures. This process extends their viability outside of their natural environment. Recent technological innovations, including microarrays and the incorporation of predictive models like hybrid models and API algorithms, have significantly reduced the time, cost, and complexity of biopreservation processes. These technological advancements are enhancing efficiency and performance across the industry.

Moreover, multiplex cellular imaging platforms are emerging as a transformative technology in the biopreservation field. These platforms improve the ability to monitor disease progression and offer insights into suitable diagnostic and treatment measures. They are particularly useful for specific healthcare areas like cardiology, gynecology, and point-of-care diagnostics. As these innovations progress, the role of biopreservation in modern healthcare is expected to expand.

Product Segmentation Insights:

The equipment segment dominated the biopreservation market in 2022, accounting for 78.75% of the market share. This is largely due to the growing demand for bio-banking services, which are used to preserve stem cells, DNA, plasma, and tissue cultures. The ability of biopreservation equipment to provide adequate storage capacity while requiring minimal maintenance has contributed to the widespread adoption of these solutions. As more healthcare providers and research facilities adopt biopreservation technologies, the equipment segment is expected to continue its strong performance.

The media segment, although smaller in market share, has significant growth potential. It is a crucial element of the biopreservation process, ensuring that biological materials are preserved effectively. The media segment is projected to grow at a remarkable CAGR of 29.99% from 2023 to 2030. Media applications are becoming more sophisticated, offering features that enhance research by enabling better data sharing and analysis. These advancements allow researchers to improve their capabilities in diagnosing, monitoring, and treating various health conditions, which is expected to drive significant market growth over the forecast period. As a result, the media segment will play an increasingly important role in advancing the overall effectiveness and efficiency of biopreservation.

Order a free sample PDF of the Biopreservation Market Intelligence Study, published by Grand View Research.

[crimsonpublishers-oabb]

Binomial Population of Biological Objects

Let the system consist of n of the same type and independent biological individuals with the same indicator p survival at a given interval [0,T] time [1]. Let us assume that a population is subject to an epidemic that leads to the death of some of the individuals. For this population, it has been established that it saves itself from extinction if the condition of survivability is met r ≤ d where r and d - the number of individuals, dying on [0,T], and the maximum allowable (critical) value of the quantity r. In another notation, this condition has the form qˆ0 ≤ q , where qˆ = r n and q0 = r0 n - the proportion of individuals, dying on [0,T] and its critical value [2].

Under the conditions of the example under consideration, the survivability criterion is used in the form [2]

Read More About This Article: https://crimsonpublishers.com/oabb/fulltext/OABB.000563.php

Read More About Crimson Publishers: https://crimsonpublishers.com/oabb/index.php

[researchreportinsight]

Biopreservation Industry Analysis, Opportunities And Forecast Report, 2030

The global biopreservation market was valued at USD 2.18 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 28.30% from 2023 to 2030. The rapid growth of this market is driven by a variety of factors, including the extensive use of biopreservation in hospitals, research labs, and healthcare facilities. Increased funding from both government entities and private organizations in healthcare is bolstering this growth, alongside a rise in research and development activities. In addition, advancements in product development are contributing to the expanding market. For instance, BioLife Solutions introduced a high-capacity controlled freezer in April 2021, targeting the cell and gene therapy market, which enabled the company to extend its product offerings.

Despite the market's expansion, the COVID-19 pandemic posed significant challenges, such as supply chain disruptions, shortages of raw materials, and interruptions to research activities. However, the pandemic also accelerated the development of novel biologics and vaccine technologies, creating a surge in demand for biologics manufacturing and preservation. As a result, opportunities for biopreservation are expected to increase, further boosting the market.

Gather more insights about the market drivers, restrains and growth of the Biopreservation Market

Biopreservation involves maintaining the integrity and functionality of biological materials such as stem cells, DNA, tissues, and organs by storing them at specific temperatures. This process extends their viability outside of their natural environment. Recent technological innovations, including microarrays and the incorporation of predictive models like hybrid models and API algorithms, have significantly reduced the time, cost, and complexity of biopreservation processes. These technological advancements are enhancing efficiency and performance across the industry.

Moreover, multiplex cellular imaging platforms are emerging as a transformative technology in the biopreservation field. These platforms improve the ability to monitor disease progression and offer insights into suitable diagnostic and treatment measures. They are particularly useful for specific healthcare areas like cardiology, gynecology, and point-of-care diagnostics. As these innovations progress, the role of biopreservation in modern healthcare is expected to expand.

Product Segmentation Insights:

The equipment segment dominated the biopreservation market in 2022, accounting for 78.75% of the market share. This is largely due to the growing demand for bio-banking services, which are used to preserve stem cells, DNA, plasma, and tissue cultures. The ability of biopreservation equipment to provide adequate storage capacity while requiring minimal maintenance has contributed to the widespread adoption of these solutions. As more healthcare providers and research facilities adopt biopreservation technologies, the equipment segment is expected to continue its strong performance.

The media segment, although smaller in market share, has significant growth potential. It is a crucial element of the biopreservation process, ensuring that biological materials are preserved effectively. The media segment is projected to grow at a remarkable CAGR of 29.99% from 2023 to 2030. Media applications are becoming more sophisticated, offering features that enhance research by enabling better data sharing and analysis. These advancements allow researchers to improve their capabilities in diagnosing, monitoring, and treating various health conditions, which is expected to drive significant market growth over the forecast period. As a result, the media segment will play an increasingly important role in advancing the overall effectiveness and efficiency of biopreservation.

Order a free sample PDF of the Biopreservation Market Intelligence Study, published by Grand View Research.

[healthcaremarketanalysis]

RNA Analysis Industry worth $9.9 billion by 2028, with a CAGR of 13.4%

The global RNA analysis market growth forecasted to transform from USD 5.3 billion in 2023 to USD 9.9 billion by 2028, driven by a CAGR of 13.4%. Various elements such as increasing R&D activities, increasing government funding for drug discovery research, and growing pharmaceutical & biological industries are the major growth factors for this market. Many peptide-based research projects are also being fostered by increasing collaborative partnerships among various companies that are driving market growth.

Download an Illustrative overview:

Browse in-depth TOC on "RNA Analysis Market"

178 - Tables

46 - Figures

263 - Pages

The reagents/consumables segment accounted for the largest share of the product & service segment in the RNA analysis market in 2022.

Based on product & service, the RNA analysis market is segmented into reagents/consumables, instruments, software, and services. In 2022, the reagents/consumables segment accounted for the largest share of the RNA analysis market. The large share of this segment is fueled by the increasing demand for omics-based therapeutics, expanding research and development activities, and the availability of various RNA analysis reagents in the market.

The PCR segment accounted for the largest share of the technology segment in the RNA analysis market in 2022.

Based on technology, the RNA analysis market is segmented into PCR, sequencing, microarrays, and RNA interference. The PCR segment accounted for the largest share in the RNA analysis market in 2022. PCR is associated with several advantages, such as ease of operation, and short production cycles. These advantages support the growth of the PCR in the RNA analysis segment.

Asia Pacific is likely to grow at the highest growth rate during the forecast period.

Based on the region The global RNA analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional segment. The Asia Pacific region is estimated to grow at the highest CAGR in the RNA analysis market during the forecast period. The growth of the pharmaceuticals market in the region is primarily driven by the increasing prevalence of chronic diseases, the rising disposable incomes, the growing focus on personalized medicine, and the increasing government support for genomics and proteomics.

Request Sample Pages:

RNA Analysis Market Dynamics:

Drivers:

Growing demand for personalized medicine

Restraints:

High capital investments

Opportunities:

Opportunities in Emerging Countries

Challenges:

Data management in transcriptomics research

Key Market Players:

The prominent players operating in the RNA analysis market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), and Eurofins Scientific (Luxembourg).

Recent Developments:

In October 2022, Agilent Technologies and CMP Scientific Corp. entered into a co-marketing agreement to provide an integrated capillary electrophoresis-mass spectrometry (CE-MS) solution for the life science and pharmaceutical industries.

In March 2022, Eurofins acquired Beacon Discovery, a drug discovery-based CRO. Beacon supported the fully integrated drug discovery programs from target validation to pre-clinical candidates.

In January 2021, Thermo Fisher acquired Phitonex to provide greater flow cytometry and imaging multiplexing capabilities for protein and cell analysis research needs. Phitonex's product offerings are also an expansion of the company's existing protein and cell analysis portfolio.

Get 10% Free Customization on this Report:

RNA Analysis Market Advantages:

Unraveling Gene Expression: RNA analysis allows researchers to study the dynamic gene expression patterns in cells and tissues, providing valuable insights into how genes are regulated and how they respond to different stimuli, disease conditions, or treatments.

Disease Understanding: By analyzing RNA profiles, scientists can gain a deeper understanding of the molecular basis of various diseases, including cancer, neurological disorders, and infectious diseases. This knowledge can lead to the identification of biomarkers and potential therapeutic targets.

Personalized Medicine: RNA analysis has the potential to enable personalized medicine approaches. By profiling an individual's RNA, clinicians can tailor treatments to the patient's specific genetic makeup and disease characteristics, increasing treatment efficacy and minimizing adverse effects.

Advancements in Therapeutics: RNA analysis plays a crucial role in the development of novel RNA-based therapeutics, such as RNA interference (RNAi) and mRNA vaccines. These groundbreaking treatments have the potential to target specific genes and revolutionize disease management.

Diagnostic Applications: RNA analysis offers a wide range of diagnostic applications. From detecting infectious agents to identifying specific genetic mutations associated with diseases, RNA-based diagnostic tests can provide faster, more accurate results than traditional methods.

Biotechnology and Drug Development: In the biotechnology and pharmaceutical industries, RNA analysis is utilized to assess the safety and efficacy of potential drugs. It helps identify potential drug targets and provides valuable information during preclinical and clinical trials.

Agricultural Advancements: RNA analysis is also applied in agriculture to improve crop yields, develop disease-resistant varieties, and enhance the nutritional content of food.

Non-Invasive Testing: In certain cases, RNA analysis can be performed on non-invasive samples such as blood, urine, or saliva, reducing the need for invasive procedures and making it easier to monitor patients over time.

Technological Advancements: The RNA analysis market is continuously evolving with advancements in sequencing technologies, bioinformatics, and automation. These innovations have led to increased throughput, reduced costs, and improved accuracy in data analysis.

Research Tools: The availability of diverse RNA analysis tools and kits allows researchers to perform experiments efficiently and cost-effectively, fostering a broader adoption of RNA-focused studies across academic and commercial laboratories.

Overall, the growing advantages of RNA analysis have positioned it as a pivotal component in advancing our understanding of biology, driving medical breakthroughs, and shaping the future of personalized medicine and precision healthcare.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

[deshpandeisha]

Advancements in Diagnostic Techniques for Veterinary Infectious Diseases

The global veterinary infectious disease diagnostics market size was USD 1.70 Billion in 2021 and is expected to register a CAGR of 9.1% during the forecast period. The veterinary infectious disease diagnostics market refers to the tools and methods used to diagnose infectious diseases in animals. This market is expected to grow significantly in the coming years, driven by several factors.

One of the primary drivers of growth in the veterinary infectious disease diagnostics market is the increasing prevalence of infectious diseases in animals. According to the Centers for Disease Control and Prevention (CDC), infectious diseases are responsible for a significant portion of illnesses and deaths in animals. The increasing prevalence of infectious diseases is leading to an increased demand for veterinary infectious disease diagnostics from pet owners and animal healthcare providers.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample/1824

The leading market contenders listed in the report are: IDEXX, Thermo Fisher Scientific, Heska Corporation, Neogen Corporation, QIAGEN, Randox Laboratories Ltd, BIOMÉRIEUX, Virbac, Zoetis, and BioChek

The research study examines historic. The timeline makes the report an invaluable resource for readers, investors, and stakeholders looking for key insights in readily accessible documents with the information presented in the form of tables, charts, and graphs. To Visit Full Report & Table of Contents Veterinary Infectious Disease Diagnostics Market: https://www.emergenresearch.com/industry-report/veterinary-infectious-disease-diagnostics-market

Market Overview: The report bifurcates the Veterinary Infectious Disease Diagnostics market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment. Segments Covered in this report are:

Technology Outlook (Revenue, USD Billion; 2019-2030)

Immunodiagnostics

Lateral Flow Assays

ELISA Tests

Molecular Diagnostics

PCR Tests

Microarrays

Animal Type Outlook (Revenue, USD Billion; 2019-2030)

Companion Animals

Food-Producing Animals

End-use Outlook (Revenue, USD Billion; 2019-2030)

Veterinary Hospital & Clinics

Veterinary Reference Laboratories

Point of Care/ In-House Testing

Veterinary Research Institutes & Universities

The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market. Get An Impressive Discount On This Report@ https://www.emergenresearch.com/request-discount/1824

Regional Analysis Covers: North America (U.S., Canada) Europe (U.K., Italy, Germany, France, Rest of EU) Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) Latin America (Chile, Brazil, Argentina, Rest of Latin America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Key reasons to buy the Global Veterinary Infectious Disease Diagnostics Market report:

The latest report comprehensively studies the global Veterinary Infectious Disease Diagnostics market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.

The report offers an insightful analysis of the regional outlook of the market.

It offers a detailed account of the end-use applications of the products & services offered by this industry.

The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.

[elucidata]

GEO Datasets for Transcriptomics Meta-Analysis: Unlocking Hidden Insights

Meta-analysis is a powerful statistical method that enables researchers to combine and analyze data from multiple studies, providing a broader perspective and more robust findings. In transcriptomics research, where the focus is on studying gene expression patterns, meta-analysis plays a crucial role in uncovering molecular signatures that may not be apparent in single studies due to limited sample sizes or variability.

This blog aims to empower transcriptomics researchers by providing insights into effective meta-analysis techniques. By leveraging available transcriptomics databases like GEO (Gene Expression Omnibus), ArrayExpress, and SRA, researchers can enhance their investigations and contribute to scientific progress. Polly, a tool designed to enhance data usability, helps make this data actionable, enabling researchers to streamline their analyses and gain deeper insights.

GEO Datasets for Impactful Meta-Analysis

The Gene Expression Omnibus (GEO) is an invaluable resource for transcriptomics, offering a vast array of publicly available gene expression data, including microarrays, RNA sequencing, etc. GEO facilitates global data sharing, enabling researchers to explore gene expression patterns, uncover molecular mechanisms, and investigate links to diseases. This collaborative platform encourages data reuse, scientific discovery, and open sharing within the genomics community.

Original Publish